The study of the treatment of non-small cell lung cancer by the combination therapy of cetuximab and ramucirumab

Abstract

Objective Explore the target West to rituximab and remo combination on cell A549 Lo mAb treatment of non-small cell lung cancer and its effect mechanism. Methods Detection of epidermal growth factor receptor (EGFR)/vascular endothelial growth factor receptor 2 (VEGFR2) expression in A549 cell surface; detection effect of cetuximab and General Administration of the A549 Lo monoclonal antibody combined with cell proliferation, migration, antibody dependent cellular cytotoxicity (ADCC) and related signal pathway. Results In combination with cetuximab and A549 cells was 90.5%, antibody binding rate was 27% Lu remo. Cetuximab, monoclonal antibody, CO administration of Remo Lu had inhibitory effect on A549 cells, in a dose-dependent manner; cetuximab, Remo Lo mAb group cell migration is relatively slow, with the slowest cell migration group; drug combination can be a very good mediated cell killing effect, better than the West rituximab group and remo Lu co administration of monoclonal antibody group; simultaneously blocking EGFR and phosphorylation of KDR, protein kinase B (Akt) and p38, resulting in the extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathway was strongly inhibited. Conclusion After combined treatment of antibodies targeting EGFR and VEGFR2, the proliferation and cell migration of A549 cells were decreased, and the ADCC function was enhanced. Combined administration significantly improved the antitumor effect of single drug. Key words: Epidermal growth factor receptor; Vascular endothelial growth factor receptor 2; Non-small-cell lung carcinoma